Avantra Family Wealth Inc. Takes $398,000 Position in Pfizer Inc. (NYSE:PFE)

Avantra Family Wealth Inc. bought a new stake in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 14,992 shares of the biopharmaceutical company’s stock, valued at approximately $398,000.

A number of other large investors have also recently modified their holdings of the stock. SYM FINANCIAL Corp boosted its stake in shares of Pfizer by 209.0% during the 4th quarter. SYM FINANCIAL Corp now owns 21,483 shares of the biopharmaceutical company’s stock valued at $570,000 after purchasing an additional 14,531 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Pfizer by 2.3% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 158,076 shares of the biopharmaceutical company’s stock valued at $4,194,000 after purchasing an additional 3,557 shares in the last quarter. Coerente Capital Management boosted its stake in shares of Pfizer by 0.8% during the 4th quarter. Coerente Capital Management now owns 593,678 shares of the biopharmaceutical company’s stock valued at $15,750,000 after purchasing an additional 4,626 shares in the last quarter. Symphony Financial Ltd. Co. boosted its stake in shares of Pfizer by 15.5% during the 4th quarter. Symphony Financial Ltd. Co. now owns 47,477 shares of the biopharmaceutical company’s stock valued at $1,252,000 after purchasing an additional 6,371 shares in the last quarter. Finally, Costello Asset Management INC boosted its stake in shares of Pfizer by 35.1% during the 4th quarter. Costello Asset Management INC now owns 76,900 shares of the biopharmaceutical company’s stock valued at $2,040,000 after purchasing an additional 19,975 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $26.51 on Friday. The company has a 50 day moving average price of $26.27 and a 200-day moving average price of $27.86. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $150.20 billion, a PE ratio of 35.82, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.49%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s payout ratio is 232.44%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on PFE. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup lowered their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Guggenheim lowered their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.